ScholarLens Back to search
2007•NeurologyRequires access

Response to carbamazepine in children with newly diagnosed partial onset epilepsy

Katherine D. Holland, Tracy A. Glauser

Open publisher page 10 citations

Abstract

OBJECTIVE: The purpose of this work is to characterize the effectiveness and therapeutic doses of carbamazepine (CBZ) in children with localization-related epilepsy. METHODS: Treatment to initial CBZ monotherapy and doses associated with 1-year seizure freedom were examined in 100 consecutive children with partial epilepsy. RESULTS: Of the 100 patients studied, 55 became seizure-free on CBZ monotherapy, 10 did not tolerate CBZ within the first 3 months of therapy owing to either hypersensitivity or intolerable side effects, and 35 continued to have seizures. In children age <12, over 95% responded at doses below 17.5 mg/kg/day; in children age >12, over 95% responded at below 15 mg/kg/day. CONCLUSIONS: We suggest that other antiepileptic treatments be considered when seizures continue in children taking carbamazepine doses between 15 and 17.5 mg/kg/day even if side effects are absent.

About this research paper

What this paper is about

OBJECTIVE: The purpose of this work is to characterize the effectiveness and therapeutic doses of carbamazepine (CBZ) in children with localization-related epilepsy. METHODS: Treatment to initial CBZ monotherapy and doses associated with 1-year seizure freedom were examined in 100 consecutive children with partial epilepsy. RESULTS: Of the 100 patients studied, 55 became seizure-free on CBZ monotherapy, 10 did not tolerate CBZ within the first 3 months of therapy owing to either hypersensitivity or intolerable side effects, and 35 continued to have seizures. In children age <12, over 95% responded at doses below 17.5 mg/kg/day; in children age >12, over 95% responded at below 15 mg/kg/day. CONCLUSIONS: We suggest that other antiepileptic treatments be considered when seizures continue in children taking carbamazepine doses between 15 and 17.5 mg/kg/day even if side effects are absent.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: The purpose of this work is to characterize the effectiveness and therapeutic doses of carbamazepine (CBZ) in children with localization-related epilepsy. METHODS: Treatment to initial CBZ monotherapy and doses associated with 1-year seizure freedom were examined in 100 consecutive children with partial epilepsy. RESULTS: Of the 100 patients studied, 55 became seizure-free on CBZ monotherapy, 10 did not tolerate CBZ within the first 3 months of therapy owing to either hypersensitivity or intolerable side effects, and 35 continued to have seizures. In children age <12, over 95% responded at doses below 17.5 mg/kg/day; in children age >12, over 95% responded at below 15 mg/kg/day. CONCLUSIONS: We suggest that other antiepileptic treatments be considered when seizures continue in children taking carbamazepine doses between 15 and 17.5 mg/kg/day even if side effects are absent.

Key concepts: Carbamazepine, Partial epilepsy, Epilepsy, partial seizures, Complex partial seizures, Medicine, Pediatrics, Psychiatry

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Response to carbamazepine in children with newly diagnosed partial onset epilepsy — Research Paper | ScholarLens